Abstract
Abstract
Background:
Widespread inappropriate antibiotic prescribing is a major driver of resistance. Little is known about antifungal prescribing practices in the United States, which is concerning given emerging resistance in fungi, particularly to azole antifungal agents.
Objective:
We analyzed outpatient antifungal prescribing data in the United States to inform stewardship efforts.
Design:
Descriptive analysis of outpatient antifungal prescriptions dispensed during 2018 in the IQVIA Xponent database.
Methods:
Prescriptions were summarized by drug, sex, age, geography, and healthcare provider specialty. Census denominators were used to calculate prescribing rates among demographic groups.
Results:
Healthcare providers prescribed 22.4 million antifungal courses in 2018 (68 prescriptions per 1,000 persons). Fluconazole was the most commonly prescribed drug (75%), followed by terbinafine (11%) and nystatin (10%). Prescription rates were higher among females versus males (110 vs 25 per 1,000 population) and adults versus children (82 vs 27 per 1,000 population). Prescription rates were highest in the South (81 per 1,000 population) and lowest in the West (48 per 1,000 population). Nurse practitioners and family practitioners prescribed the most antifungals (43% of all prescriptions), but the highest prescribing rates were among obstetrician-gynecologists (84 per provider).
Conclusions:
Prescribing antifungal drugs in the outpatient setting is common, with enough courses dispensed for 1 in every 15 US residents in 2018. Fluconazole use patterns suggest vulvovaginal candidiasis as a common indication. Regional prescribing differences could reflect inappropriate use or variations in disease burden. Further study of higher antifungal use in the South could help target antifungal stewardship practices.
Publisher
Cambridge University Press (CUP)
Reference18 articles.
1. Variability in antifungal utilization among neonatal, pediatric, and adult inpatients in academic medical centers throughout the United States of America
2. 8. Bridged-race population estimates, 1990–2018. Centers for Disease Control and Prevention website. http://wonder.cdc.gov/bridged-race-v2018.html. Published 2018. Accessed January 9, 2020.
3. 13. Vulvovaginal candidiasis. Centers for Disease Control and Prevention website. https://www.cdc.gov/std/treatment-guidelines/candidiasis.htm. Published 2021. Accessed October 18, 2021.
4. 16. FDA Drug Safety Communication: FDA warns that prescribing of nizoral (ketoconazole) oral tablets for unapproved uses including skin and nail infections continues; linked to patient death. US Food and Drug Administration website. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-prescribing-nizoral-ketoconazole-oral-tablets-unapproved. Accessed October 4, 2021.
5. Influence of drug class and healthcare setting on systemic antifungal expenditures in the United States, 2005–15
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献